IP Library Granted Patent US 9,453,009
Granted Patent B2
US 9,453,009 · App. 14/566,244 · Granted Sep 27, 2016

Synthesis of deuterated morpholine derivatives

Inventors: Julie F. Liu (Lexington, MA); Xuejun Tang (Ellicott City, MD); Scott L. Harbeson (Cambridge, MA); Craig E. Masse (Cambridge, MA)
Assignee: Concert Pharmaceuticals, Inc.
C07D413/10A61K31/5377A61K45/06C07C215/12C07D263/06C07D295/02C07D295/033C07D295/06C07D295/12C07D295/135C07D413/14C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,453,009
App. No.
14/566,244
Granted
Sep 27, 2016
Kind
B2
Abstract

The present invention is directed to a process for preparing a 2,26,6-d 4 -morpholine derivative represented by Structural Formula (I): or a salt thereof.

Claims (15)

1. A compound represented by Formula (I):

or a salt thereof, wherein

R 1 is —OH, —NO, —NH 2 , —NHR a , —N(R a ) 2 , —C(═O)NR c R d , —C(═O)OR g , -phthalimido, —SO 2 —R b , or a group selected from alkyl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, wherein the alkyl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, and heterocycloalkylalkyl are each independently optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, —OR e , —C(═O)OR e , —C(═O)R e , —NO 2 , —CN, —NH 2 , —NHR a , —N(R a ) 2 , —NR c C(═O)R e , —C(═O)NR c R d , —S(O)R e , —S(O) 2 R e , —SR e , and —SO 2 NR c R d , wherein each C 1-6 alkyl is optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, —OH, C 1-6 haloalkyl and C 1-6 haloalkoxy;

each R a is independently an alkyl optionally substituted with halogen, C 1-6 alkyl, C 1-6 alkoxy, —OH, C 1-6 haloalkyl or C 1-6 haloalkoxy;

R b is alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which is optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, —OR e , —C(═O)OR e , —C(═O)R e , —NO 2 , —CN, —NH 2 , —NHR a , —N(R a ) 2 , —NR c C(═O)R e , —C(═O)NR c R d , —S(O)R e , —S(O) 2 R e , —SR e , and —SO 2 NR c R d , wherein each C 1-6 alkyl is optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, —OH, C 1-6 haloalkyl and C 1-6 haloalkoxy;

R c and R d are each independently —H or alkyl optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, —OR e , —C(═O)OR e , —C(═O)R e , —NO 2 , —CN, —NH 2 , —NHR a , —N(R a ) 2 , —NR c C(═O)R e , —C(═O)NR c R d , —S(O)R e , —S(O) 2 R e , —SR e , and —SO 2 NR c R d , wherein each C 1-6 alkyl is optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, —OH, C 1-6 haloalkyl and C 1-6 haloalkoxy;

R e is —H or alkyl optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, —OR f , —C(═O)OR f , —C(═O)R f , —NO 2 , —CN, —NH 2 , —NHR a , —N(R a ) 2 , —NR c C(═O)R f , —C(═O)NR c R d , —S(O)R f , —S(O) 2 R f , —SR f , and —SO 2 NR c R d , wherein each C 1-6 alkyl substituent is optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, —OH, C 1-6 haloalkyl and C 1-6 haloalkoxy;

R f is alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

R g is alkyl optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, —OR f , —C(═O)OR f , —C(═O)R f , —NO 2 , —CN, —NH 2 , —NHR a , —N(R a ) 2 , —NR c C(═O)R f , —C(═O)NR c R d , —S(O)R f , —S(O) 2 R f , —SR f , and —SO 2 NR c R d , wherein each C 1-6 alkyl substituent is optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, —OH, C 1-6 haloalkyl and C 1-6 haloalkoxy; and

R 4 , R 4′ , R 5 and R 5′ are each independently —H or C 1-4 alkyl optionally substituted with one or more halogen, C 1-6 alkyl, C 1-6 alkoxy, —OH, C 1-6 haloalkyl, or C 1-6 haloalkoxy;

and wherein the deuterium enrichment at each position designated as deuterium is at least about 85%.

2. The compound of claim 1 , wherein each of R 4 , R 4′ , R 5 and R 5′ is hydrogen; and wherein the deuterium enrichment at each position designated as deuterium is at least about 95%.

3. The compound of claim 1 , wherein R 1 is benzyl, —SO 2 -aryl, or —SO 2 -heteroaryl.

4. The compound of claim 2 , wherein R 1 is benzyl.

5. The compound of claim 1 , wherein R e is alkyl optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, —NO 2 , —CN, —NH 2 , —NHR a , —N(R a ) 2 , —C(═O)NR c R d , and —SO 2 NR c R d , wherein each C 1-6 alkyl substituent is optionally substituted with one or more groups selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, —OH, C 1-6 haloalkyl and C 1-6 haloalkoxy.

Assignments (3)
MERGER Recorded Aug 2, 2023
From: CONCERT PHARMACEUTICALS, INC.
To: SUN PHARMACEUTICAL INDUSTRIES, INC.
Reel/Frame 064465/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2015
From: LIU, JULIE F.; TANG, XUEJUN; HARBESON, SCOTT L.; MASSE, CRAIG E.
To: CONCERT PHARMACEUTICALS, INC.
Reel/Frame 035290/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2015
From: LIU, JULIE F.; TANG, XUEJUN; HARBESON, SCOTT L.; MASSE, CRAIG E.
To: CONCERT PHARMACEUTICALS, INC.
Reel/Frame 035125/0942 →
Continuity (4)
Continuation 13678093 · Nov 15, 2012
Continuation 12456507 · Jun 17, 2009
Provisional Application 61132284 · Jun 17, 2008
Related Publication 20150099714A1 · Apr 9, 2015